Squarepoint Ops LLC Has $608,000 Holdings in Cytokinetics, Incorporated $CYTK

Squarepoint Ops LLC decreased its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 82.3% in the second quarter, Holdings Channel reports. The fund owned 18,398 shares of the biopharmaceutical company’s stock after selling 85,480 shares during the period. Squarepoint Ops LLC’s holdings in Cytokinetics were worth $608,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. EverSource Wealth Advisors LLC increased its stake in shares of Cytokinetics by 723.7% in the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 673 shares during the period. Hantz Financial Services Inc. grew its holdings in Cytokinetics by 2,872.7% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,308 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 1,264 shares during the last quarter. UMB Bank n.a. increased its position in Cytokinetics by 37.8% in the 2nd quarter. UMB Bank n.a. now owns 1,593 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 437 shares during the period. Assetmark Inc. lifted its holdings in shares of Cytokinetics by 127.6% during the second quarter. Assetmark Inc. now owns 2,642 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 1,481 shares during the last quarter. Finally, J.Safra Asset Management Corp boosted its position in shares of Cytokinetics by 17.8% in the second quarter. J.Safra Asset Management Corp now owns 3,381 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 511 shares during the period.

Analyst Ratings Changes

A number of brokerages recently issued reports on CYTK. HC Wainwright boosted their target price on shares of Cytokinetics from $120.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday. JMP Securities restated a “market outperform” rating and issued a $78.00 price target on shares of Cytokinetics in a research report on Tuesday, September 2nd. Citigroup reaffirmed a “market outperform” rating on shares of Cytokinetics in a research report on Monday. Cantor Fitzgerald reissued an “overweight” rating on shares of Cytokinetics in a research report on Tuesday, October 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a research note on Wednesday, October 8th. Fifteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and a consensus target price of $83.61.

Insider Activity

In other Cytokinetics news, CEO Robert I. Blum sold 5,000 shares of Cytokinetics stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $55.05, for a total transaction of $275,250.00. Following the completion of the transaction, the chief executive officer directly owned 368,108 shares of the company’s stock, valued at approximately $20,264,345.40. This trade represents a 1.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward M. Md Kaye sold 28,064 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $66.72, for a total transaction of $1,872,430.08. Following the completion of the sale, the director directly owned 9,977 shares in the company, valued at approximately $665,665.44. The trade was a 73.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 168,494 shares of company stock valued at $10,811,018. 3.40% of the stock is owned by company insiders.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: FDA approved Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy, turning Cytokinetics into a commercial-stage cardiology biotech and opening a new revenue runway — a primary driver behind the rally. Article Title
• Positive Sentiment: Multiple brokers lifted price targets and reiterated buy/outperform views (Barclays, Morgan Stanley, BofA, Needham, Citizens/JMP), signaling stronger analyst conviction on commercial prospects and supporting upside. Article Title
• Positive Sentiment: Unusually heavy call-option buying (about 5,619 calls, ~103% above typical daily volume) suggests traders are positioning for additional upside or near-term bullish moves. (Options volume report)
• Positive Sentiment: Analyst commentary highlights practical label advantages for MYQORZO vs. the incumbent (flexible dosing), and management targets substantial market share gains — commentary that supports a multi-quarter adoption story. Article Title
• Neutral Sentiment: Citizens maintained its Market Outperform rating on CYTK, which is supportive but not a new endorsement. Article Title
• Negative Sentiment: Insider selling: director Wendell Wierenga sold 20,000 shares at an average $66.14 (Dec. 22), trimming his stake ~38% — a potential short-term headwind or cautionary signal for some investors. SEC Filing

Cytokinetics Stock Down 3.5%

NASDAQ CYTK opened at $63.29 on Wednesday. Cytokinetics, Incorporated has a twelve month low of $29.31 and a twelve month high of $70.98. The stock has a market cap of $7.74 billion, a P/E ratio of -10.06 and a beta of 0.58. The company’s 50-day simple moving average is $62.87 and its 200 day simple moving average is $49.10.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.59) by $0.05. The company had revenue of $1.94 million during the quarter, compared to analyst estimates of $6.05 million. The company’s quarterly revenue was up 318.1% on a year-over-year basis. During the same period in the previous year, the company posted ($1.36) earnings per share. Research analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.